

## SUPPLEMENTARY TABLES

**Supplementary Table 3. Main characteristics of included studies.**

| <i>IGF-1</i> SNP | Study      | Race  | Patients    | Case/Control | HWE     |
|------------------|------------|-------|-------------|--------------|---------|
| rs35767          | Li,2014    | Asian | PMOP female | 216/220      | 0.998   |
|                  | Li,2015    | Asian | PMOP female | 485/485      | 0.932   |
|                  | Wei,2015   | Asian | PMOP female | 272/272      | 0.979   |
|                  | This study | Asian | PMOP female | 95/222       | 0.782   |
| rs2288377        | Li,2014    | Asian | PMOP female | 216/220      | <0.001* |
|                  | Li,2015    | Asian | PMOP female | 485/485      | <0.001* |
|                  | This study | Asian | PMOP female | 95/222       | 0.879   |
| rs5742612        | Li,2014    | Asian | PMOP female | 216/220      | <0.001* |
|                  | Li,2015    | Asian | PMOP female | 485/485      | <0.001* |
|                  | This study | Asian | PMOP female | 95/222       | 0.816   |

rs35767 Taiwan biobank MAF: 35%; 1000 Genomes MAF: 30%.

rs2288377 Taiwan biobank MAF: 29%; 1000 Genomes MAF: 10%.

rs5742612 Taiwan biobank MAF: 29%; 1000 Genomes MAF: 11%.

\*: p-value <0.05.

**Supplementary Table 4. *IGF-1* (rs35767, rs2288377, rs5742612) methodological quality of included studies.**

| Item/Study | Selection                    |                             |                       | Comparability          |                          |                               | Exposure            |   |                   |
|------------|------------------------------|-----------------------------|-----------------------|------------------------|--------------------------|-------------------------------|---------------------|---|-------------------|
|            | Adequate definition of cases | Representative of the cases | Selection of controls | Definition of controls | Control for age and BMI: | Control for additional factor | Exposure assessment | Same method of ascertainment for all subjects | Non-response rate |
| Li, 2014   | a                            | a                           | b                     | a                      | a                        | b                             | a                   | a   | a                 |
| Li, 2015   | a                            | a                           | b                     | a                      | a                        | a                             | a                   | a   | a                 |
| Wei, 2015  | a                            | a                           | b                     | a                      | a                        | a                             | a                   | a   | b                 |

Adequate definition of cases : a: yes, with independent validation. b: yes, eg record linkage or based on self reports. c: no description.

Representativeness of the cases : a: consecutive or obviously representative series of cases; b: potential for selection biases or not stated.

Selection of Controls : a: community controls. b: hospital controls. c: no description.

Definition of Controls : a: no history of disease. b: no description of source.

Control for age and BMI : a: Yes. b: No.

Control for additional factor : a: Yes. b: No.

Exposure assessment : a: secure record (eg surgical records) b: structured interview where blind to case/control status. c: interview not blinded to case/control status. d: written self report or medical record only. e: no description.

Same method of ascertainment for all subjects : a: Yes. b: No.

Non-response rate : a: same rate for both groups. b: non respondents described. c: rate different and no designation.